+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Myelodysplastic Syndrome Market by Product Type (Branded, Generic), Therapy Line (First Line, Second Line, Third Line), End User, Treatment Type, Distribution Channel - Global Forecast 2025-2030- Product Image
Myelodysplastic Syndrome Market by Product Type (Branded, Generic), Therapy Line (First Line, Second Line, Third Line), End User, Treatment Type, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Myelodysplastic Syndrome Market by Product Type (Branded, Generic), Therapy Line (First Line, Second Line, Third Line), End User, Treatment Type, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968770
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Myelodysplastic Syndrome Market grew from USD 2.84 billion in 2024 to USD 3.14 billion in 2025. It is expected to continue growing at a CAGR of 10.10%, reaching USD 5.07 billion by 2030.

Pioneering the Future of Myelodysplastic Syndrome Management Through In-Depth Examination of Therapeutic Advances and Unmet Patient Imperatives

The landscape of Myelodysplastic Syndrome embodies a complex interplay of clinical innovation, evolving patient demographics, and shifting regulatory frameworks. As diagnostic precision improves, an expanding array of therapeutic pathways emerges alongside nuanced considerations of safety and efficacy. Transitioning from one-size-fits-all approaches toward personalized treatment regimens, stakeholders in both public and private sectors are challenged to integrate molecular insights, such as genetic and epigenetic biomarkers, into standard care pathways.

Moreover, patient advocacy groups and provider networks are increasingly influential in shaping research priorities, driving momentum toward therapies that address both hematologic parameters and quality-of-life outcomes. As new entrants vie to differentiate their pipelines, collaboration among clinical investigators, payers, and community oncologists becomes indispensable. Consequently, the initial phase of this executive summary establishes foundational knowledge of key drivers shaping clinical trials, reimbursement landscapes, and multidisciplinary care models that ultimately inform strategic decision making across the Myelodysplastic Syndrome continuum.

Revolutionary Changes Reshaping Myelodysplastic Syndrome Care Through Innovative Therapeutics Patient Stratification and Collaborative Research Initiatives

In recent years, the Myelodysplastic Syndrome landscape has witnessed transformative shifts driven by breakthroughs in targeted therapies and immunomodulatory agents. Precision medicine initiatives have intensified, resulting in innovative mechanisms designed to reactivate tumor suppressor pathways and modulate aberrant immune responses. Consequently, pharmaceutical developers are increasingly prioritizing hypomethylating agents and IDH inhibitors to capitalize on molecular subtypes that promise improved safety profiles and extended survival benchmarks.

Furthermore, digital health platforms and telemedicine integration have revolutionized patient monitoring, enabling real-time data capture of hematologic parameters and treatment adherence. Collaborative efforts between academic institutions and biotechnology firms have accelerated early-phase trials, while adaptive regulatory pathways have reduced barriers for accelerated approvals. Thus, the confluence of advanced analytics, patient-centric care models, and strategic partnerships has fundamentally recalibrated how therapies are developed, approved, and delivered to individuals living with Myelodysplastic Syndrome.

Assessing the Cascading Effects of United States Tariff Revisions on Myelodysplastic Syndrome Treatment Modalities Supply Chains and Cost Structures

The implementation of revised United States tariff policies has introduced multifaceted implications for the import and distribution of critical therapeutics used in Myelodysplastic Syndrome care. By increasing duties on active pharmaceutical ingredients and finished dosage imports, supply chains have encountered heightened cost pressures, compelling manufacturers and distributors to reevaluate sourcing agreements and contractual frameworks. Additionally, transitional compliance protocols have created temporary bottlenecks at key ports of entry, resulting in irregular delivery schedules and inventory shortfalls for hospital pharmacies and specialty clinics.

Moreover, healthcare providers are exploring nearshoring strategies, seeking regional partners to mitigate the risk of further tariff volatility. As organizations navigate these evolving trade dynamics, many are reassessing their pricing models to preserve accessibility for patients reliant on transfusion support, hypomethylating therapies, and targeted agents. In response, commercial leaders are reengineering distribution networks to optimize logistics, while regulatory teams engage in proactive advocacy to influence policy revisions that align national trade interests with patient needs.

Unlocking Market Potential Through Detailed Segmentation Insights Spanning Product Types Therapy Lines End Users Treatment Modalities and Channels

A nuanced segmentation framework reveals the intricate market realities across diverse treatment categories and care settings. Within the realm of product type, the dynamic interplay between branded innovations and generic equivalents underscores competitive pricing pressures and formulary positioning. In parallel, therapy lines differentiate market needs: initial treatment strategies demand tolerability and rapid hematologic response, second-line options focus on resistance management, while third-line interventions emphasize quality-of-life maintenance in refractory cases.

At the level of treatment type, chemotherapy agents such as cytarabine and daunorubicin remain foundational, yet hypomethylating compounds-namely azacitidine, decitabine, and guadecitabine-are capturing clinical interest due to epigenetic modulation capabilities. Alongside these, immunomodulators including lenalidomide, pomalidomide, and thalidomide offer alternative pathways to address cytopenias. Supportive care elements such as growth factors and blood transfusions continue to underpin symptomatic relief, whereas targeted therapies like IDH inhibitors-particularly enasidenib and ivosidenib-plus luspatercept and venetoclax, are reshaping treatment algorithms.

End users range from hospital-based hematology units to outpatient specialty clinics and home healthcare services, each demanding tailored service models and supply chain solutions. Distribution channels encompassing both offline and online platforms further influence market penetration strategies and patient access initiatives. This holistic segmentation insight illuminates where value creation can be optimized across the Myelodysplastic Syndrome continuum.

Interpreting Regional Nuances in Myelodysplastic Syndrome Care with Focus on Americas Europe Middle East Africa and Asia-Pacific Growth Drivers

Regional dynamics exert profound influence on access to Myelodysplastic Syndrome therapies, as geographical nuances dictate policy frameworks, reimbursement pathways, and clinical practice patterns. In the Americas, large-scale public and private payer systems drive volume procurement for hypomethylating agents and targeted therapies, while patient assistance programs mitigate affordability barriers. Cross-border collaborations facilitate real-world evidence generation, accelerating inclusion of novel agents in national formularies.

Meanwhile, within Europe, Middle East, and Africa, regulatory harmonization initiatives and pan-regional consortiums streamline clinical trial conduct, enhancing patient recruitment efficiency and data sharing. National health technology assessment bodies emphasize health economic endpoints, prompting manufacturers to demonstrate cost-effectiveness through robust pharmacoeconomic modeling. Moreover, sub-Saharan healthcare infrastructure investments are expanding access to supportive care and diagnostic platforms.

Across Asia-Pacific, rapidly growing oncology markets hinge on local manufacturing capacities and public-private partnerships to expand treatment networks. Government-led reimbursement reforms are broadening coverage for immunomodulators and targeted therapies, while digital health innovations in remote regions bolster patient monitoring and teleconsultation. Consequently, each region presents distinct opportunities and challenges that must be addressed through adaptive strategies aligned with local regulatory and economic landscapes.

Examining the Strategic Trajectories of Leading Life Science Innovators Driving Myelodysplastic Syndrome Therapy Development and Commercial Success

Leading companies in the Myelodysplastic Syndrome domain are charting differentiated pathways to maintain competitive advantage and drive portfolio expansion. Major pharmaceutical firms continue to invest in late-stage clinical trials for next-generation hypomethylating agents, deploying adaptive trial designs to optimize dosing regimens and expand label indications. Biotechnology startups are penetrating niche segments by pioneering novel immunomodulators and targeted therapies, while forging co-development partnerships with established industry players to leverage commercial infrastructure.

Furthermore, strategic alliances between diagnostic innovators and drug developers are enhancing companion diagnostic capabilities, enabling more precise patient selection for IDH inhibitors and other targeted treatments. Concurrently, contract research organizations are scaling integrated service offerings to support complex trial protocols across multiple geographies. In addition, several regional manufacturers are pursuing biosimilar development to introduce more cost-effective alternatives for branded therapies, thereby heightening market competition and expanding access.

Formulating Pragmatic Strategies for Healthcare Executives to Accelerate Innovation Collaboration and Value-Based Outcomes in Myelodysplastic Syndrome

To capitalize on evolving market dynamics, industry leaders must implement targeted strategies that emphasize collaboration, data-driven decision making, and patient-centric care models. Investing in real-world evidence platforms and digital health partnerships will enhance outcomes tracking and facilitate adaptive manufacturing processes. In addition, co-creating value with payers through risk-sharing agreements can streamline reimbursement pathways for high-cost therapies, ensuring patient access while preserving revenue streams.

Moreover, fostering alliances between pharmaceutical developers, diagnostic companies, and provider networks will catalyze precision medicine initiatives and accelerate regulatory approvals. Deploying modular manufacturing hubs near key markets can mitigate supply chain disruptions stemming from trade policy shifts. Simultaneously, establishing robust patient support services, including telehealth counseling and home administration capabilities, will differentiate offerings in a crowded landscape. By aligning portfolio strategies with therapeutic innovations and healthcare ecosystem needs, leaders will secure sustainable growth and improve outcomes for individuals living with Myelodysplastic Syndrome.

Outlining Rigorous Mixed-Methods Research Protocols Ensuring Comprehensive Data Quality Robust Validation and Actionable Insights in Myelodysplastic Syndrome Analysis

This analysis employs a mixed-methods research design combining primary interviews, secondary data synthesis, and quantitative analytics to ensure comprehensive market insights. Primary research included structured consultations with oncologists, hematology pharmacists, payers, and patient advocacy leaders to validate clinical trends and access barriers. Concurrently, secondary research entailed reviewing peer-reviewed literature, regulatory filings, and health economic reports to corroborate therapeutic efficacy and cost-effectiveness parameters.

Quantitative models integrated real-world treatment utilization data and supply chain metrics to identify throughput constraints and pricing sensitivities. Rigorous validation protocols, including triangulation across multiple data sources and expert panel reviews, were implemented to enhance the reliability of findings. Additionally, scenario analysis was conducted to assess the potential impact of regulatory changes, tariff adjustments, and emerging therapeutic launches on market dynamics. Collectively, this robust methodology underpins the strategic recommendations and ensures that stakeholders can rely on actionable, evidence-based conclusions.

Synthesizing Key Findings to Illuminate Critical Opportunities Challenges and Strategic Pathways in the Evolving Myelodysplastic Syndrome Landscape

In conclusion, the Myelodysplastic Syndrome ecosystem is undergoing profound evolution as innovative therapies, regulatory reforms, and geopolitical dynamics converge to reshape care delivery and market accessibility. Stakeholders must navigate tariff recalibrations, complex segmentation landscapes, and diverse regional imperatives to secure competitive positioning. Moreover, the integration of precision medicine approaches and advanced data analytics will be pivotal in driving patient-centric outcomes and cost-effective care models.

By leveraging actionable insights from segmentation frameworks, regional nuances, and company strategies, industry participants can align their portfolios and operational capabilities with emerging opportunities. Ultimately, the collective efforts of pharmaceutical innovators, diagnostic developers, healthcare providers, and policy makers will determine the pace of therapeutic advancements and the extent to which patient communities benefit from novel treatment paradigms.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Branded
    • Generic
  • Therapy Line
    • First Line
    • Second Line
    • Third Line
  • End User
    • Home Healthcare
    • Hospitals
    • Specialty Clinics
  • Treatment Type
    • Chemotherapy Agents
      • Cytarabine
      • Daunorubicin
    • Hypomethylating Agents
      • Azacitidine
      • Decitabine
      • Guadecitabine
    • Immunomodulators
      • Lenalidomide
      • Pomalidomide
      • Thalidomide
    • Supportive Care
      • Blood Transfusions
      • Growth Factors
    • Targeted Therapies
      • IDH Inhibitors
        • Enasidenib
        • Ivosidenib
      • Luspatercept
      • Venetoclax
  • Distribution Channel
    • Offline
    • Online
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Bristol-Myers Squibb Company
  • Otsuka Pharmaceutical Co., Ltd.
  • Novartis International AG
  • Roche Holding AG
  • Johnson & Johnson
  • Pfizer Inc.
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advancements in targeted hypomethylating agents driving improved treatment outcomes in high-risk MDS patients
5.2. Emergence of novel gene-editing therapies aiming to correct underlying hematopoietic stem cell mutations in MDS
5.3. Growing adoption of next-generation sequencing for personalized prognosis and risk stratification in MDS management
5.4. Increasing focus on combination therapies integrating immunomodulators with standard MDS treatment regimens
5.5. Expansion of outpatient transfusion and supportive care services enhancing quality of life for MDS patients
5.6. Development of oral formulations of hypomethylating agents to improve patient adherence in MDS therapy
5.7. Rise of real-world evidence studies assessing long-term outcomes of emerging MDS therapies across diverse populations
5.8. Increased investment in biomarker-driven clinical trials to identify predictive markers of response in MDS
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Myelodysplastic Syndrome Market, by Product Type
8.1. Introduction
8.2. Branded
8.3. Generic
9. Myelodysplastic Syndrome Market, by Therapy Line
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third Line
10. Myelodysplastic Syndrome Market, by End User
10.1. Introduction
10.2. Home Healthcare
10.3. Hospitals
10.4. Specialty Clinics
11. Myelodysplastic Syndrome Market, by Treatment Type
11.1. Introduction
11.2. Chemotherapy Agents
11.2.1. Cytarabine
11.2.2. Daunorubicin
11.3. Hypomethylating Agents
11.3.1. Azacitidine
11.3.2. Decitabine
11.3.3. Guadecitabine
11.4. Immunomodulators
11.4.1. Lenalidomide
11.4.2. Pomalidomide
11.4.3. Thalidomide
11.5. Supportive Care
11.5.1. Blood Transfusions
11.5.2. Growth Factors
11.6. Targeted Therapies
11.6.1. IDH Inhibitors
11.6.1.1. Enasidenib
11.6.1.2. Ivosidenib
11.6.2. Luspatercept
11.6.3. Venetoclax
12. Myelodysplastic Syndrome Market, by Distribution Channel
12.1. Introduction
12.2. Offline
12.3. Online
13. Americas Myelodysplastic Syndrome Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Myelodysplastic Syndrome Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Myelodysplastic Syndrome Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Bristol-Myers Squibb Company
16.3.2. Otsuka Pharmaceutical Co., Ltd.
16.3.3. Novartis International AG
16.3.4. Roche Holding AG
16.3.5. Johnson & Johnson
16.3.6. Pfizer Inc.
16.3.7. AbbVie Inc.
16.3.8. Astellas Pharma Inc.
16.3.9. Takeda Pharmaceutical Company Limited
16.3.10. Amgen Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. MYELODYSPLASTIC SYNDROME MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. MYELODYSPLASTIC SYNDROME MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. MYELODYSPLASTIC SYNDROME MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. MYELODYSPLASTIC SYNDROME MARKET: RESEARCHAI
FIGURE 26. MYELODYSPLASTIC SYNDROME MARKET: RESEARCHSTATISTICS
FIGURE 27. MYELODYSPLASTIC SYNDROME MARKET: RESEARCHCONTACTS
FIGURE 28. MYELODYSPLASTIC SYNDROME MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. MYELODYSPLASTIC SYNDROME MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CYTARABINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CYTARABINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DAUNORUBICIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DAUNORUBICIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY AZACITIDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY AZACITIDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DECITABINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DECITABINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY GUADECITABINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY GUADECITABINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY POMALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY POMALIDOMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THALIDOMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THALIDOMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY BLOOD TRANSFUSIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY BLOOD TRANSFUSIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ENASIDENIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ENASIDENIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IVOSIDENIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IVOSIDENIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY LUSPATERCEPT, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY LUSPATERCEPT, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY VENETOCLAX, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY VENETOCLAX, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 139. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 140. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 141. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 142. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 143. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 146. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 147. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 148. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 149. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 150. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 151. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 152. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 153. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 154. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 155. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2024 (USD MILLION)
TABLE 156. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2025-2030 (USD MILLION)
TABLE 157. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2018-2024 (USD MILLION)
TABLE 158. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2025-2030 (USD MILLION)
TABLE 159. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 162. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 163. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 164. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 165. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 168. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 169. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 170. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 171. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 172. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 173. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 174. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 175. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 176. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 177. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2024 (USD MILLION)
TABLE 178. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2025-2030 (USD MILLION)
TABLE 179. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2018-2024 (USD MILLION)
TABLE 180. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2025-2030 (USD MILLION)
TABLE 181. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 254. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 258. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 260. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 262. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 264. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 266. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2024 (USD MILLION)
TABLE 268. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2025-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2018-2024 (USD MILLION)
TABLE 270. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2025-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 274. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 275. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 276. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 277. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 280. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 281. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 282. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 283. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 284. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 285. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 286. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 287. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 288. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 289. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2024 (USD MILLION)
TABLE 290. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2025-2030 (USD MILLION)
TABLE 291. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2018-2024 (USD MILLION)
TABLE 292. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2025-2030 (USD MILLION)
TABLE 293. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 296. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 297. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 298. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 299. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 300. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 301. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 302. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 303. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
TABLE 304. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2030 (USD MILLION)
TABLE 305. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 306. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY HYPOMETHYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 307. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2018-2024 (USD MILLION)
TABLE 308. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IMMUNOMODULATORS, 2025-2030 (USD MILLION)
TABLE 309. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 310. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 311. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2018-2024 (USD MILLION)
TABLE 312. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TARGETED THERAPIES, 2025-2030 (USD MILLION)
TABLE 313. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2018-2024 (USD MILLION)
TABLE 314. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY IDH INHIBITORS, 2025-2030 (USD MILLION)
TABLE 315. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DISTRIBUTION

Samples

Loading
LOADING...

Companies Mentioned

  • Bristol-Myers Squibb Company
  • Otsuka Pharmaceutical Co., Ltd.
  • Novartis International AG
  • Roche Holding AG
  • Johnson & Johnson
  • Pfizer Inc.
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.14 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.07 Billion
Compound Annual Growth Rate10.1%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Myelodysplastic Syndrome Market Report 2025 - Product Image

Myelodysplastic Syndrome Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Myelodysplastic Syndrome (MDS) Drugs - Global Strategic Business Report - Product Image

Myelodysplastic Syndrome (MDS) Drugs - Global Strategic Business Report

  • Report
  • 175 Pages
  • Global
From
Myelodysplastic Syndrome (MDS) Drugs Market Report 2025 - Product Image

Myelodysplastic Syndrome (MDS) Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Myelodysplastic Syndrome Drugs Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immune Treatments), By Route Of Administration, By End-use (Hospitals, Clinics), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Myelodysplastic Syndrome Drugs Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immune Treatments), By Route Of Administration, By End-use (Hospitals, Clinics), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Myelodysplastic Syndrome Drug Pipeline Analysis Report 2025 - Product Image

Myelodysplastic Syndrome Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From

About the Myelodysplastic Syndrome Drugs Market

Myelodysplastic Syndrome (MDS) is a type of cancer that affects the bone marrow and blood cells. It is a rare disorder that can lead to anemia, infections, and bleeding. Treatment for MDS includes chemotherapy, radiation therapy, and stem cell transplantation. Drugs used to treat MDS include hypomethylating agents, such as azacitidine and decitabine, and immunomodulatory agents, such as lenalidomide and pomalidomide. These drugs are used to reduce the risk of disease progression and improve the quality of life for patients. The Myelodysplastic Syndrome Drugs market is a part of the larger Oncology Drugs market. It is a rapidly growing market, driven by the increasing prevalence of MDS and the development of new drugs. The market is expected to continue to grow in the coming years, as new drugs are developed and approved for use. Some of the major companies in the Myelodysplastic Syndrome Drugs market include Celgene Corporation, Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., and Merck & Co. Inc. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.